Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Brief description of study

This is a clinical research study of an investigational new drug device combination product of Staccato and alprazolam inhalation powder, called “Staccato ® alprazolam”. Staccato alprazolam is a single-use, hand-held, portable device that delivers a single dose of alprazolam in aerosol form (fine spray) deep into the lungs through inhalation. Staccato alprazolam is being developed for the indication of rapid cessation of a prolonged focal or generalized seizure that has not progressed to status epilepticus in patients with epilepsy 12 years of age and older. After completing the study, eligible study participants will be allowed to enroll in an open-label extension (OLE) study.

Interested participants should reach out to CECResearchStudyInfo@nyulangone.org.


Clinical Study Identifier: s21-00759
ClinicalTrials.gov Identifier: NCT05077904
Principal Investigator: Claude Steriade.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.